Multiple mechanisms of immune suppression by B lymphocytes

Molecular Medicine

Volumn 18, Issue 1, 2012, Pages 123-137

  Klinker, Matthew W ^a   Lundy, Steven K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; B LYMPHOCYTE RECEPTOR; CD5 ANTIGEN; FAS LIGAND; GRANZYME B; IMMUNOGLOBULIN G; INTERLEUKIN 10; NATURAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; SIALOPROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD5+ B CELL; CELL INTERACTION; CELL POPULATION; CYTOKINE RELEASE; DRUG MEGADOSE; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOREGULATION; INFLAMMATION; KILLER B CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFORMATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE SUBPOPULATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTIGENS, CD5; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSION; T-LYMPHOCYTES, REGULATORY;

EID: 84857025735     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00333     Document Type: Review

References (159)

1. O'Garra A, et al. (1990) Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int. Immunol. 2:821-32.
2. Nagata S, Suda T. (1995) Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16:39-43.
3. Wiley SR, et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-82.
4. Chowdhury D, Lieberman J. (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 26:389-420.
5. Nimmerjahn F, Ravetch JV. (2008) Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47.
6. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704.
7. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hy-mowitz SG. (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29:71-109.
8. Couper KN, Blount DG, Riley EM. (2008) IL-10: the master regulator of immunity to infection. J. Immunol. 180:5771-7.
9. Ferrara JL. (1993) Cytokine dysregulation as a mechanism of graft versus host disease. Curr. Opin. Immunol. 5:794-9.
10. Palomares O, et al. (2010) Role of Treg in immune regulation of allergic diseases. Eur. J. Immunol. 40:1232-40.
11. Mauri C, Blair PA. (2010) Regulatory B cells in autoimmunity: developments and controversies. Nat. Rev. Rheumatol. 6:636-43.
12. McHugh RS, Shevach EM. (2002) The role of suppressor T cells in regulation of immune responses. J. Allergy Clin. Immunol. 110:693-702.
13. Ben-Baruch A. (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16:38-52.
14. Vieira P, et al. (1991) Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc. Natl. Acad. Sci. U. S. A. 88:1172-6.
15. Mahnke K, Bedke T, Enk AH. (2007) Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell. Immunol. 250:1-13.
16. Shimamura T, Habu S, Hashimoto K, Sasaki S. (1984) Feedback suppression of the immune response in vivo. III. Lyt-1+ B cells are suppressor-inducer cells. Cell. Immunol. 83:221-4.
17. Lopez DM, Blomberg BB, Padmanabhan RR, Bourguignon LY. (1989) Nuclear disintegration of target cells by killer B lymphocytes from tumor-bearing mice. FASEB J. 3:37-43.
18. O'Garra A, et al. (1992) Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 22:711-7.
19. Wolf SD, Dittel BN, Hardardottir F, Janeway CA. (1996) Experimental autoimmune encephalo -myelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184:2271-8.
20. Sabat R, et al. (2010) Biology of interleukin-10. Cytokine Growth Factor Rev. 21:331-44.
21. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209-20.
22. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. (1991) IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-22.
23. de Waal Malefyt R, et al. (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibil-ity complex expression. J. Exp. Med. 174:915-24.
24. Ding L, Linsley PS, Huang LY, Germain RN, She-vach EM. (1993) IL-10 inhibits macrophage costim-ulatory activity by selectively inhibiting the up-reg-ulation of B7 expression. J. Immunol. 151:1224-34.
25. Willems F, et al. (1994) Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 24:1007-9.
26. Del Prete G, et al. (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150:353-60.
27. Groux H, Bigler M, de Vries JE, Roncarolo MG. (1996) Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 184:19-29.
28. Groux H, Bigler M, de Vries JE, Roncarolo MG. (1998) Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J. Immunol. 160:3188-93.
29. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. (2002) B cells regulate autoimmu-nity by provision of IL-10. Nat. Immunol. 3:944-50.
30. Mizoguchi A, Mizoguchi E, Takedatsu H, Blum-berg RS, Bhan AK. (2002) Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 16:219-30.
31. Mauri C, Gray D, Mushtaq N, Londei M. (2003) Prevention of arthritis by interleukin 10-produc-ing B cells. J. Exp. Med. 197:489-501.
32. Hussain S, Delovitch TL. (2007) Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-de-pendent manner. J. Immunol. 179:7225-32.
33. Haas KM, et al. (2010) Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J. Immunol. 184:4789-800.
34. Watanabe R, et al. (2010) Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J. Immunol. 184:4801-9.
35. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182:7459-72.
36. Yanaba K, et al. (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28:639-50.
37. Hayakawa K, et al. (1999) Positive selection of natural autoreactive B cells. Science. 285:113-6.
38. Yang M, et al. (2010) Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J. Immunol. 184:3321-5.
39. Bhattacharyya S, et al. (2011) NFATc1 affects mouse splenic B cell function by controlling the calcineurin-NFAT signaling network. J. Exp. Med. 208:823-39.
40. Matsumoto M, et al. (2011) The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity. 34:703-14.
41. Evans JG, et al. (2007) Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178:7868-78.
42. Ding Q, et al. (2011) Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 121:3645-56.
43. DiLillo DJ, Matsushita T, Tedder TF. (2010) B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. N. Y. Acad. Sci. 1183:38-57.
44. Blair PA, et al. (2010) CD19+ CD24(hi) CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 32:129-40.
45. Iwata Y, et al. (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 117:530-41.
46. Griffin DO, Holodick NE, Rothstein TL. (2011) Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J. Exp. Med. 208:67-80.
47. Rousset F, et al. (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 89:1890-3.
48. Trapani JA, Sutton VR. (2003) Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 15:533-43.
49. Jahrsdorfer B, et al. (2006) B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after in-terleukin-21-based activation. Blood. 108:2712-9.
50. Hagn M, et al. (2009) Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J. Immunol. 183:1838-45.
51. Hagn M, et al. (2010) CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B. Eur. J. Immunol. 40:2060-9.
52. Srivastava RK. (2001) TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neopla-sia. 3:535-46.
53. Takahashi T, et al. (1994) Generalized lymphopro-liferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-76.
54. Puck JM, Sneller MC. (1997) ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Semin. Immunol. 9:77-84.
55. Song K, et al. (2000) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191:1095-104.
56. Hahne M, et al. (1996) Activated B cells express functional Fas ligand. Eur. J. Immunol. 26:721-4.
57. Lundy SK. (2009) Killer B lymphocytes: the evidence and the potential. Inflamm. Res. 58:345-57.
58. Villunger A, et al. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood. 90:12-20.
59. Silvestris F, Tucci M, Cafforio P, Dammacco F. (2001) Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood. 97:1155-64.
60. Kojima Y, et al. (2006) Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur. J. Haematol. 76:465-72.
61. Tinhofer I, et al. (1998) Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood. 91:4273-81.
62. Tanner JE, Alfieri C. (1999) Epstein-Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T-cell apoptosis. Blood. 94:3439-47.
63. Samuelsson A, Sonnerborg A, Heuts N, Coster J, Chiodi F. (1997) Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses. 13:1031-8.
64. Rich RF, Cook WJ, Green WR. (2006) Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of anti-retroviral CTL. Virology. 346:287-300.
65. Lundy SK, Lerman SP, Boros DL. (2001) Soluble egg antigen-stimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL(+) T and B cells during murine Schisto-soma mansoni infection. Infect. Immun. 69:271-80.
66. Lundy SK, Boros DL. (2002) Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by inter-leukin 4 (IL-4) and IL-10. Infect. Immun. 70:812-9.
67. Tian J, et al. (2001) Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167:1081-9.
68. Bonardelle D, Benihoud K, Kiger N, Bobe P. (2005) B lymphocytes mediate Fas-dependent cytotoxic-ity in MRL/lpr mice. J. Leukoc. Biol. 78:1052-9.
69. Lundy SK, Fox DA. (2009) Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Res. Ther. 11:R128.
70. Lundy SK, Berlin AA, Martens TF, Lukacs NW. (2005) Deficiency of regulatory B cells increases allergic airway inflammation. Inflamm. Res. 54:514-21.
71. Minagawa R, et al. (2004) The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen. Transplantation. 78:799-806.
72. Takeda K, et al. (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195:161-9.
73. Sedger LM, et al. (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32:2246-54.
74. Sedger LM, et al. (2010) Extreme lymphoprolifer-ative disease and fatal autoimmune thrombocy-topenia in FasL and TRAIL double-deficient mice. Blood. 115:3258-68.
75. Mariani SM, Krammer PH. (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28:973-82.
76. Secchiero P, et al. (2005) Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J. Cell. Physiol. 205:246-52.
77. Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F. (2003) Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br. J. Haematol. 122:39-52.
78. Mariani SM, Krammer PH. (1998) Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28:1492-8.
79. Kemp TJ, Moore JM, Griffith TS. (2004) Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J. Immunol. 173:892-99.
80. Agata Y, et al. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8:765-72.
81. Ishida Y, Agata Y, Shibahara K, Honjo T. (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887-95.
82. Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR. (1997) Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp. Cell. Res. 232:25-8.
83. Yamazaki T, et al. (2002) Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169:5538-45.
84. Loke P, Allison JP. (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. U. S. A. 100:5336-41.
85. Akbari O, et al. (2010) PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-depen-dent airway hyperreactivity in opposing directions. Mucosal Immunol. 3:81-91.
86. Latchman Y, et al. (2001) PD-L2 is a second lig-and for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261-8.
87. Tseng SY, et al. (2001) B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:839-46.
88. Carter LL, et al. (2007) PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 182:124-34.
89. Singh AK, Stock P, Akbari O. (2011) Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy. 66:155-62.
90. Zhong, X, Tumang JR, Gao W, Bai C, Rothstein TL. (2007) PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur. J. Immunol. 37:2405-10.
91. Zhong X, et al. (2009) A novel subpopulation of B-1 cells is enriched with autoreactivity in normal and lupus-prone mice. Arthritis Rheum. 60:3734-43.
92. Fehr J, Hofmann V, Kappeler U. (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N. Engl. J. Med. 306:1254-8.
93. Imbach P, et al. (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1:1228-31.
94. Parekh RB, et al. (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 316:452-7.
95. Kaneko Y, Nimmerjahn F, Ravetch JV. (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 313:670-3.
96. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U. S. A. 105:19571-8.
97. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 475:110-3.
98. Bruhns P, Samuelsson A, Pollard JW, Ravetch J V. (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 18:573-81.
99. Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T. (2000) Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J. Biochem. 128:621-8.
100. Wang J, et al. (2011) Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol. Cell. Pro-teomics. 10:M110.004655.
101. You Y, et al. (2011) Marginal zone B cells regulate antigen capture by marginal zone macrophages. J. Immunol. 186:2172-81.
102. Herzenberg LA. (2000) B-1 cells: the lineage question revisited. Immunol. Rev. 175:9-22.
103. Shaw PX, et al. (2000) Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105:1731-40.
104. Shaw PX, Goodyear CS, Chang MK, Witztum JL, Silverman GJ. (2003) The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J. Immunol. 170:6151-7.
105. Chen Y, Park YB, Patel E, Silverman GJ. (2009) IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J. Immunol. 182:6031-43.
106. Chen Y, et al. (2009) Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J. Immunol. 183:1346-59.
107. Binder CJ, et al. (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9:736-43.
108. Binder CJ, et al. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114:427-37.
109. Shevach EM. (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 30:636-45.
110. Ashour HM, Niederkorn JY. (2006) Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation. J. Immunol. 176:5950-7.
111. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN. (2007) B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 178:3447-56.
112. Carter NA, et al. (2011) Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J. Immunol. 186:5569-79.
113. Sun JB, Flach CF, Czerkinsky C, Holmgren J. (2008) B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B sub-unit. J. Immunol. 181:8278-87.
114. Singh A, et al. (2008) Regulatory role of B cells in a murine model of allergic airway disease. J. Immunol. 180:7318-26.
115. Amu S, et al. (2010) Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J. Allergy Clin. Immunol. 125:1114-24.
116. Zhong X, et al. (2007) Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur. J. Immunol. 37:2400-4.
117. Soukhareva N, Jiang Y, Scott DW. (2006) Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell. Immunol. 240:41-6.
118. Ahangarani RR, et al. (2009) In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. J. Immunol. 183:8232-43.
119. Chen X, Jensen PE. (2007) Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J. Immunol. 179:2046-50.
120. Zheng J, et al. (2009) Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells. J. Immunol. 183:3742-50.
121. Mieza MA, et al. (1996) Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J. Immunol. 156:4035-40.
122. Gombert JM, et al. (1996) Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur. J. Immunol. 26:2989-98.
123. Chiba A, et al. (2004) Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 50:305-13.
124. Miyamoto K, Miyake S, Yamamura T. (2001) A synthetic glycolipid prevents autoimmune en-cephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:531-4.
125. Singh AK, et al. (2001) Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1801-11.
126. Sonoda KH, Stein-Streilein J. (2002) CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur. J. Immunol. 32:848-57.
127. Wei B, et al. (2005) Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc. Natl. Acad. Sci. U. S. A. 102:2010-5.
128. Hayakawa Y, et al. (2001) Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 166:6012-8.
129. Varadhachary AS, Perdow SN, Hu C, Rama-narayanan M, Salgame P. (1997) Differential ability of T cell subsets to undergo activation-induced cell death. Proc. Natl. Acad. Sci. U. S. A. 94:5778-83.
130. Roberts AI, et al. (2003) The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol. Res. 28:285-93.
131. Irmler M, et al. (1997) Inhibition of death receptor signals by cellular FLIP. Nature. 388:190-5.
132. Chao DT, Korsmeyer SJ. (1998) BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16:395-419.
133. Zhang L, Miller RG, Zhang J. (1996) Characterization of apoptosis-resistant antigen-specific T cells in vivo. J. Exp. Med. 183:2065-73.
134. Gupta S, Gollapudi S. (2008) CD95-mediated apoptosis in naive, central and effector memory subsets of CD4+ and CD8+ T cells in aged humans. Exp. Gerontol. 43:266-74.
135. Zhang X, et al. (1997) Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185:1837-49.
136. Akdis M, et al. (2003) T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J. 17:1026-35.
137. Watanabe N, et al. (1997) Th1 and Th2 subsets equally undergo Fas-dependent and -independent activation-induced cell death. Eur. J. Immunol. 27:1858-64.
138. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. (2002) Interferon gamma is required for activation-induced death of T lymphocytes. J. Exp. Med. 196:999-1005.
139. Varadhachary AS, Peter ME, Perdow SN, Kram-mer PH, Salgame P. (1999) Selective up-regula-tion of phosphatidylinositol 3′-kinase activity in Th2 cells inhibits caspase-8 cleavage at the death-inducing complex: a mechanism for Th2 resistance from Fas-mediated apoptosis. J. Immunol. 163:4772-9.
140. Boise LH, et al. (1995) CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 3:87-98.
141. Kishimoto H, Sprent J. (1999) Strong TCR liga-tion without costimulation causes rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells. J. Immunol. 163:1817-26.
142. Banz A, Pontoux C, Papiernik M. (2002) Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J. Immunol. 169:750-7.
143. Singh N, et al. (2010) CD4+ CD25+ regulatory T cells resist a novel form of CD28- and Fas-dependent p53-induced T cell apoptosis. J. Immunol. 184:94-104.
144. Fritzsching B, et al. (2005) In contrast to effector T cells, CD4+ CD25+ FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J. Immunol. 175:32-6.
145. Rahman MK, et al. (2010) The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival. J. Immunol. 184:7247-56.
146. Shi G, et al. (2009) Unlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell death. J. Immunol. 183:7547-56.
147. Niederkorn JY, Mayhew E. (1995) Role of splenic B cells in the immune privilege of the anterior chamber of the eye. Eur. J. Immunol. 25:2783-7.
148. Leite-de-Moraes MC, et al. (2000) Fas/Fas lig-and interactions promote activation-induced cell death of NK T lymphocytes. J. Immunol. 165:4367-71.
149. Wilson MT, et al. (2003) The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. U. S. A. 100:10913-8.
150. Martin F, Kearney JF. (2001) B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 13:195-201.
151. Yoshimoto M, et al. (2011) Embryonic day 9 yolk sac and intra-embryonic hemogenic endothe-lium independently generate a B-1 and marginal zone progenitor lacking B-2 potential. Proc. Natl. Acad. Sci. U. S. A. 108:1468-73.
152. Montecino-Rodriguez E, Leathers H, Dorshkind K. (2006) Identification of a B-1 B cell-specified progenitor. Nat. Immunol. 7:293-301.
153. Martin F, Oliver AM, Kearney JF. (2001) Marginal zone and B1 B cells unite in the early response against T-independent blood-borne par-ticulate antigens. Immunity. 14:617-29.
154. Allman D, Pillai S. (2008) Peripheral B cell subsets. Curr. Opin. Immunol. 20:149-57.
155. Sampalo A, Brieva JA. (2002) Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape. Leuk. Lymphoma. 43:881-4.
156. Mullauer L, Mosberger I, Chott A. (1998) Fas ligand expression in nodal non-Hodgkin's lym-phoma. Mod. Pathol. 11:369-75.
157. Amel Kashipaz MR, et al. (2003) Assessment of Be1 and Be2 cells in systemic lupus erythemato-sus indicates elevated interleukin-10 producing CD5+ B cells. Lupus. 12:356-63.
158. Blenman KR, et al. (2006) IL-10 regulation of lupus in the NZM2410 murine model. Lab. Invest. 86:1136-48.
159. Chong W P, et al. (2004) Association of inter-leukin-10 promoter polymorphisms with systemic lupus erythematosus. Genes Immun. 5:484-92.